COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #131
Source   Share   Tweet
See all 143 studies
Late treatment study
Dabbous et al., Research Square, doi:10.21203/ (Preprint)
A Randomized Controlled Study Of Favipiravir Vs Hydroxych loroquine In COVID-19 Management: What Have We Learned So Far?
Small RCT comparing HC Q and favipiravir, with 50 patients in each arm, finding that 55.1% of HC Q patients were PCR negative on day 7 compared to 48% for favipiravir, p = 0.7. There was no comparison with a control group.
Source   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.